Grifols (GRFS) Cash from Investing Activities Growth (3y) (2013 - 2020)
Grifols (GRFS) Cash from Investing Activities Growth (3y) (2013 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-78.48% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-32.26% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-4.78% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-12.88% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
-27.30% |
| Dec 31, 2019 |
-53.53% |
| Dec 31, 2018 |
37.09% |
| Jun 30, 2018 |
-36.08% |
| Mar 31, 2018 |
31.30% |
| Dec 31, 2017 |
183.32% |
| Jun 30, 2017 |
26.51% |
| Mar 31, 2017 |
4.58% |
| Dec 31, 2016 |
-47.99% |
| Sep 30, 2016 |
-127.15% |
| Dec 31, 2015 |
-182.62% |
| Sep 30, 2015 |
68.94% |
| Jun 30, 2015 |
727.86% |
| Mar 31, 2015 |
-1,804.80% |
| Dec 31, 2014 |
61.45% |
| Sep 30, 2014 |
-6.98% |
| Jun 30, 2014 |
-16.43% |
| Mar 31, 2014 |
322.02% |
| Dec 31, 2013 |
-27.07% |
| Sep 30, 2013 |
64.75% |
